Immuneering investor relations
Witryna28 lut 2024 · 28.02.2024 - CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) - Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company … Witryna11 kwi 2024 · Immuneering Corporation IMRX shares soared 18.5% in the last trading session to close at $11.59. The move was backed by solid volume with far more …
Immuneering investor relations
Did you know?
Witryna3 lis 2024 · Date: November 29, 2024. Time: 10:30-10:55 am ET. 5th Annual Evercore ISI HealthCONx Conference, Virtual. Format: Fireside Chat. Date: December 1, 2024. … Witryna12 kwi 2024 · Format: Virtual Presentation and 1x1 Investor Meetings Virtual Presentation: April 19 from 12:45 - 1:25 pm ET in Track 1. The presentations will be webcast live and archived for 30 days in the Investor Relations section of Immuneering’s website at Events & Presentations Immuneering Corporation. …
Witryna28 lut 2024 · The presentations will be webcast live and archived for 90 days in the Investor Relations section of Immuneering’s website at Events & Presentations. About Immuneering Corporation. Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to … WitrynaFinancial statements and reports for Immuneering Corp USD0.001 A including annual reports and financial results for the last 5 years. ... Investor relations; Corporate …
Witryna24 sty 2024 · Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy … Witryna1 dzień temu · The presentations will be webcast live and archived for 30 days in the Investor Relations section of Immuneering's website at Events & Presentations Immuneering Corporation. About Immuneering ...
WitrynaGet the latest Immuneering Corp (IMRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …
WitrynaImmuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non … description of a plastic surgeonWitryna30 mar 2024 · Immuneering News: This is the News-site for the company Immuneering on Markets Insider description of a physiotherapistWitrynaFormat: Virtual Presentation and 1x1 Investor Meetings Virtual Presentation: April 19 from 12:45 - 1:25 pm ET in Track 1 The presentations will be webcast live and archived for 30 days in the Investor Relations section of Immuneering s website at Events & Presentations Immuneering Corporation . About Immuneering Corporation Ñ description of a pirate shipWitrynaImmuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and … description of a pineappleWitryna12 kwi 2024 · Format: Virtual Presentation and 1x1 Investor Meetings Virtual Presentation: April 19 from 12:45 - 1:25 pm ET in Track 1. The presentations will be … chs infusion centerWitryna25 sie 2024 · CAMBRIDGE, Mass., Aug. 25, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using … chs informationWitryna1 dzień temu · Format: Virtual Presentation and 1x1 Investor Meetings Virtual Presentation: April 19 from 12:45 - 1:25 pm ET in Track 1. The presentations will be webcast live and archived for 30 days in the Investor Relations section of Immuneering’s website at Events & Presentations Immuneering Corporation. description of a pirate